Pfizer Valuation
Is PFE * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of PFE * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: PFE * (MX$536) is trading below our estimate of fair value (MX$1303.37)
Significantly Below Fair Value: PFE * is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for PFE *?
Key metric: As PFE * is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is PFE *'s PE Ratio? | |
|---|---|
| PE Ratio | 34.2x |
| Earnings | US$4.27b |
| Market Cap | US$146.38b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 3.5x |
| Enterprise Value/EBITDA | 11.4x |
| PEG Ratio | 2x |
Price to Earnings Ratio vs Peers
How does PFE *'s PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 19.5x | ||
LAB B Genomma Lab Internacional. de | 15.5x | 19.8% | Mex$24.6b |
SAN Sanofi | 25.6x | 17.9% | €115.5b |
NOVN Novartis | 18x | 7.0% | CHF 186.7b |
ROG Roche Holding | 19.1x | 11.2% | CHF 203.9b |
PFE * Pfizer | 34.2x | 16.8% | Mex$146.4b |
Price-To-Earnings vs Peers: PFE * is expensive based on its Price-To-Earnings Ratio (34.2x) compared to the peer average (19.5x).
Price to Earnings Ratio vs Industry
How does PFE *'s PE Ratio compare vs other companies in the Global Pharmaceuticals Industry?
| 24 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 24 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: PFE * is expensive based on its Price-To-Earnings Ratio (34.2x) compared to the Global Pharmaceuticals industry average (22.5x).
Price to Earnings Ratio vs Fair Ratio
What is PFE *'s PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 34.2x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate PFE *'s Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | Mex$536.00 | Mex$661.14 +23.3% | 13.9% | Mex$914.06 | Mex$507.81 | n/a | 24 |
| Nov ’25 | Mex$572.30 | Mex$668.72 +16.8% | 13.1% | Mex$900.72 | Mex$540.43 | n/a | 23 |
| Oct ’25 | Mex$569.00 | Mex$661.29 +16.2% | 13.4% | Mex$886.61 | Mex$531.96 | n/a | 22 |
| Sep ’25 | Mex$569.52 | Mex$625.89 +9.9% | 13.0% | Mex$847.49 | Mex$508.49 | n/a | 22 |
| Aug ’25 | Mex$575.96 | Mex$612.37 +6.3% | 13.8% | Mex$838.35 | Mex$503.01 | n/a | 22 |
| Jul ’25 | Mex$518.00 | Mex$532.70 +2.8% | 15.1% | Mex$751.09 | Mex$450.65 | n/a | 22 |
| Jun ’25 | Mex$484.95 | Mex$532.70 +9.8% | 15.1% | Mex$751.09 | Mex$450.65 | n/a | 22 |
| May ’25 | Mex$439.99 | Mex$519.71 +18.1% | 15.4% | Mex$739.62 | Mex$427.34 | n/a | 22 |
| Apr ’25 | Mex$459.67 | Mex$548.13 +19.2% | 18.6% | Mex$838.07 | Mex$435.79 | n/a | 22 |
| Mar ’25 | Mex$452.08 | Mex$557.72 +23.4% | 18.4% | Mex$852.40 | Mex$443.25 | n/a | 23 |
| Feb ’25 | Mex$466.00 | Mex$563.93 +21.0% | 19.3% | Mex$854.33 | Mex$444.25 | n/a | 22 |
| Jan ’25 | Mex$487.37 | Mex$558.95 +14.7% | 19.9% | Mex$845.62 | Mex$388.98 | n/a | 22 |
| Dec ’24 | Mex$496.00 | Mex$694.99 +40.1% | 23.1% | Mex$1,289.78 | Mex$550.30 | n/a | 22 |
| Nov ’24 | Mex$550.00 | Mex$728.77 +32.5% | 22.4% | Mex$1,335.92 | Mex$569.99 | Mex$572.30 | 22 |
| Oct ’24 | Mex$579.00 | Mex$760.63 +31.4% | 21.3% | Mex$1,284.46 | Mex$548.04 | Mex$569.00 | 22 |
| Sep ’24 | Mex$612.50 | Mex$744.41 +21.5% | 21.0% | Mex$1,261.28 | Mex$538.14 | Mex$569.52 | 23 |
| Aug ’24 | Mex$603.15 | Mex$770.41 +27.7% | 19.9% | Mex$1,264.60 | Mex$590.15 | Mex$575.96 | 23 |
| Jul ’24 | Mex$629.58 | Mex$792.52 +25.9% | 19.2% | Mex$1,283.40 | Mex$598.92 | Mex$518.00 | 22 |
| Jun ’24 | Mex$667.00 | Mex$819.34 +22.8% | 18.8% | Mex$1,316.51 | Mex$614.37 | Mex$484.95 | 22 |
| May ’24 | Mex$698.00 | Mex$888.42 +27.3% | 16.1% | Mex$1,357.31 | Mex$723.90 | Mex$439.99 | 22 |
| Apr ’24 | Mex$732.99 | Mex$940.36 +28.3% | 16.0% | Mex$1,396.58 | Mex$744.84 | Mex$459.67 | 22 |
| Mar ’24 | Mex$729.76 | Mex$944.06 +29.4% | 15.3% | Mex$1,378.92 | Mex$735.42 | Mex$452.08 | 21 |
| Feb ’24 | Mex$821.82 | Mex$960.58 +16.9% | 15.1% | Mex$1,396.58 | Mex$744.84 | Mex$466.00 | 21 |
| Jan ’24 | Mex$995.00 | Mex$1,070.14 +7.6% | 12.3% | Mex$1,472.93 | Mex$864.12 | Mex$487.37 | 21 |
| Dec ’23 | Mex$978.92 | Mex$1,043.99 +6.6% | 12.6% | Mex$1,456.03 | Mex$854.20 | Mex$496.00 | 21 |
| Nov ’23 | Mex$945.03 | Mex$1,069.88 +13.2% | 13.7% | Mex$1,495.72 | Mex$877.49 | Mex$550.00 | 19 |
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.
Discover undervalued companies
CSPC Pharmaceutical Group
HK$69.4b
An investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People’s Republic of China, other Asian regions, North America, Europe, and internationally.
1093 N
HK$15.69
7D
0%
1Y
-27.0%
Exact Sciences
US$13.1b
Provides cancer screening and diagnostic test products in the United States and internationally.
EXAS *
US$872.00
7D
0%
1Y
n/a
GSK
UK£54.8b
Engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally.
GSK1 N
UK£367.94
7D
0%
1Y
n/a